度拉糖肽与2型糖尿病青少年的肾小球高滤过、蛋白尿及白蛋白尿:AWARD-PEDS研究的事后分析
该研究为AWARD-PEDS试验的事后分析,纳入154名10-18岁2型糖尿病青少年,比较度拉糖肽与安慰剂对肾功能的影响。结果显示度拉糖肽组eGFR下降更明显(-5.8 vs -0.1 mL/min/1.73 m2,P=0.016),且肾小球高滤过和蛋白尿患病率在度拉糖肽组下降而安慰剂组上升。结论认为度拉糖肽与肾小球高滤过和蛋白尿减轻相关,但对糖尿病肾病风险的影响尚不明确。
要点
- 度拉糖肽组eGFR从基线至26周下降-5.8 mL/min/1.73 m2,安慰剂组下降-0.1 mL/min/1.73 m2(P=0.016)。
- eGFR下降主要见于基线存在肾小球高滤过的参与者。
- 26周时,安慰剂组肾小球高滤过和蛋白尿患病率增加,度拉糖肽组下降(分别P=0.014和P=0.004 vs 安慰剂)。
核心结论
- 度拉糖肽与2型糖尿病青少年的肾小球高滤过和蛋白尿减轻相关,但这些变化对糖尿病肾病风险的影响尚不明确。
研究设计与样本
- 对已完成的一项度拉糖肽安慰剂对照血糖控制试验中的肾脏实验室数据进行事后分析,纳入154名10-18岁2型糖尿病青少年。
主要发现
- 度拉糖肽组eGFR从基线至26周下降-5.8 mL/min/1.73 m2,安慰剂组下降-0.1 mL/min/1.73 m2(P=0.016)。
- eGFR下降主要见于基线存在肾小球高滤过的参与者。
- 26周时,安慰剂组肾小球高滤过和蛋白尿患病率均增加,度拉糖肽组均下降(分别P=0.014和P=0.004 vs 安慰剂)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo. RESEARCH DESIGN AND METHODS: Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide. RESULTS: Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.8 vs. -0.1 mL/min/1.73 m2; P = 0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively). CONCLUSIONS: Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.
引用
- Bjornstad P, Arslanian SA, Hannon TS, et al. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024. PMID: 38954432. doi:10.2337/dc24-0322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。